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The clinical use of glucocorticoids both in mothers threatened with preterm labour and in 
preterm neonates has become common practice in the last 40 years [1][2].  This treatment 
is based on the pioneering work of Liggins who discovered that the development of the fetal 
tissues in preparation for extra-uterine life was dependent upon the pre-partum surge in 10 
fetal endogenous glucocorticoids and that exposure to synthetic glucocorticoids in 
premature offspring could aid the development of the pulmonary system [3][4][5]. It is now 
established that antenatal glucocorticoid therapy accelerates fetal lung maturation [6] and 
that treatment of the preterm infant with glucocorticoids reduces the incidence of chronic 
lung disease and the baby’s dependence on assisted ventilation [7][8]. Ante- and post-natal 15 
glucocorticoid therapy has therefore significantly reduced the incidence of morbidity and 
mortality in the preterm infant [6], and it is one of the best examples of the successful 
translation of basic experimental science into human clinical practice [9]. 
 
Physiological effects of glucocorticoids in the perinatal period 20 
In the adult individual, glucocorticoids are well known mediators of physiological responses 
to stress.  Endogenous production occurs in the adrenal cortex, and exogenous synthetic 
analogues are frequently administered clinically as anti-inflammatory or immuno-
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modulatory treatments [10]. During the fetal period, glucocorticoids take on a pivotal role 
as orchestrators of fetal organ maturation.  This fetal maturation is stimulated by a prenatal 25 
surge in circulating levels of fetal plasma glucocorticoid in most species studied [11]. We 
now know that this pre-partum surge in fetal plasma glucocorticoid is intricately linked with 
the appropriate preparation of many organ systems to ensure the successful transition from 
intra- to extra-uterine life.  Some of the key changes are summarised in Figure 1 below. For 
instance, the fetal lungs are filled with fluid and relatively inelastic [12]. However, the 30 
neonate must be able to inflate the lungs with air to begin ventilation immediately after 
birth. As development progresses to term, fetal lung liquid begins to be reabsorbed [13] and 
elastin mRNA levels increase [14].  Further, pulmonary surfactant protein expression 
increases and, histologically, surfactant granules can be seen in type II pneumocytes [15]. All 
these changes in the pulmonary system have been shown in vivo and in vitro to rely on the 35 
surge in fetal circulating levels of glucocorticoids [6][15] .   
 
In the fetal brain, the relationship between the pre-partum cortisol surge and the 
development of the central nervous system is complex, and the various cell populations and 
brain regions are affected differently. Neurogenesis occurs predominantly during early 40 
gestation, however by late gestation there are still principal events occurring including 
multiplication of glia and astrocytes, programmed cell death, neuronal migration, synapse 
formation and pruning, as well as myelination [16]. Fetal glucocorticoids are thought to be 
highly involved in the physiological regulation of all of these processes, by altering cell 
number and size within specific populations, promoting changes in synaptic function [17] 45 
and by balancing apoptosis in the developing brain [18]. 
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Fetal plasma glucocorticoids are also involved in the development and maturation of the 
cardiovascular system. Fetal arterial blood pressure increases with advancing gestational 
age [19][20]. This change can be experimentally induced preterm by exogenous 50 
administration of synthetic glucocorticoids [21][22]. Similarly, the fetal arterial baroreflex 
undergoes changes in set point and sensitivity to accommodate the ontogenic rise in fetal 
arterial blood pressure with advancing gestation.  These effects can be mimicked preterm by 
exogenous administration of synthetic glucocorticoids, promoting an accelerated rightward 
shift in the fetal cardiac baroreflex, thereby allowing a greater resting arterial blood 55 
pressure in the fetus without triggering sustained fetal bradycardia [22].  There are also 
significant developmental effects of glucocorticoids on the fetal heart [2]. They stimulate 
cardiomyocyte maturation, specifically hypertrophy and bi-nucleation [23]. Left ventricular 
developed pressure also increases towards term [24] and the electrical conduction system 
in the heart is also matured in preparation for the increased cardiac workload at birth [23].  60 
The capacity of the fetal cardiovascular system to respond to acute stress also changes with 
advancing gestational age in parallel with the prepartum surge in fetal plasma glucocorticoid 
[21][25].  In response to an acute period of fetal oxygen deprivation, a fall in fetal heart rate 
occurs and there is an increase in fetal peripheral vascular resistance, contributing to a 
redistribution of the fetal cardiac output away from peripheral circulations.  Fetal 65 
bradycardia reduces myocardial oxygen consumption and the redistribution of blood flow is 
part of the well-known fetal brain sparing effect [26].  We now know that in the immature 
fetus, before exposure to the pre-partum increase in fetal plasma glucocorticoid, the fetal 
bradycardia is transient and the increase in peripheral vascular resistance modest [25].  
Conversely, in the mature fetus, the fetal bradycardia is sustained and the increase in 70 
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peripheral vascular resistance very significant in response to acute hypoxia [25]. These 
maturational changes give rise to an improved myocardial oxygen sparing and a more 
efficient redistribution of the spared oxygenation towards the fetal brain [27][28]. 
Exogenous fetal treatment with synthetic glucocorticoids can switch the pattern of the fetal 
heart and circulatory responses to acute hypoxia from the immature towards the mature 75 
type, thereby enhancing the fetal defence to acute hypoxic stress[21][25][27][28].   
 
Activation of the fetal hypothalamo-pituitary-adrenal (HPA) axis is also vital for acute stress 
responses, resulting in a rapid rise in fetal blood glucocorticoid levels [29]. The sensitivity of 
the fetal HPA axis to an acute stressor also increases with gestational age, including changes 80 
in the production of pro-hormones in the fetal pituitary, such as pro-opiomelanocortin 
(POMC) [30], the bioactivity of ACTH and the increased sensitivity of the fetal adrenal cortex 
to ACTH [29].  Treatment of the immature fetus with synthetic glucocorticoids can also 
promote an increase in the sensitivity of the adrenal cortex to ACTH and thereby increase 
the magnitude of the fetal plasma endogenous glucocorticoid response to acute stress [31].   85 
 
During fetal life the kidneys do not act as the main osmoregulatory organ; a role attributed 
to the placenta. However, the fetal kidneys do produce large volumes of relatively hypo-
osmotic urine, which contributes to amniotic fluid generation [32]. The fetal kidneys are 
poor at retaining sodium (Na) and consequently have a large fractional excretion of sodium 90 
(FENa) [33]. This allows for the excretion of the large amounts of fluid that cross the 
placenta and must be lost from the fetal circulation. As gestational age increases, FENa is 
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reduced as transporters increase in number and activity in the nephron [33]; effects that can 
be induced experimentally in the preterm fetus by exogenous glucocorticoid treatment [34]. 
This prepares the fetus for the need for sodium retention upon birth to help maintain blood 95 
volume. In the sheep fetus, FENa decreases from around 15% of all Na being excreted, at 75% 
of gestation to 5% Na excretion at term, and continues to decrease during early neonatal life 
[34]. In human babies, FENa also decreases during neonatal life and glomerular filtration 
rate (GFR) in the fetal kidneys is also low.  Again, this increases towards term, in part due to 
an increased cardiac output and renal blood flow [35], with the percentage of plasma 100 
passing through the kidneys being filtered increasing from 3% to 25% in the neonate [33]. 
Maturation of the kidney is also essential for renal endocrine pathways. The renin-
angiotensin system (RAS) is vital for sodium homeostasis and long-term control of arterial 
blood pressure. Renin production increases with gestational age [36], concomitant with 
changes in expression of AT-1 and AT-2 receptors in various target organs [37]. The period 105 
of nephrogenesis occurs predominantly during late gestation in sheep  and humans [37].  In 
humans, no nephrogenesis occurs after 36 weeks [37]. The pre-partum increase in fetal 
plasma glucocorticoid has also been shown to be involved in mediating changes in fetal 
renin production [38], changes in the expression of AT-1 and AT-2 receptors in various 
target organs [39] and in mediating the decrease in nephrogenesis [36].   110 
 
Figure 1 
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Clinical benefits of glucocorticoids in the perinatal period 115 
Given the  beneficial effects of glucocorticoid exposure on numerous physiological systems 
in the fetus during late gestation, it is not surprising that antenatal glucocorticoid therapy is 
now considered to be an indispensable treatment for preterm birth by most health 
institutions. Antenatal glucocorticoids as an essential medicine for preterm labour is 
recommended by the Royal College of Obstetricians and Gynaecologists for all pregnancies 120 
at risk of preterm birth between 26-34 weeks [40]. Similarly, since 1996, the National 
Institutes of Health (NIH) in the USA has advised routine administration of synthetic 
glucocorticoids to all pregnant women at risk of delivery before 34 weeks of gestation [6]. 
Across the world, treatment for  possible preterm birth involves maternal intramuscular 
injection of the synthetic glucocorticoids, betamethasone or dexamethasone, using a variety 125 
of dosing regimens [41].  Currently, the recommended protocols are 2 doses of 12 mg of 
betamethasone or of dexamethasone intramuscularly 24 h apart, or 4 doses of 6 mg of 
dexamethasone 12 h apart [41]. 
 
Endogenous glucocorticoids, such as cortisol, are synthesised in the zona fasciculata of the 130 
adrenal cortex by the conversion of cholesterol to 21 C steroid hormones (see [42]). 
Betamethasone and dexamethasone are fluorinated synthetic analogues of cortisol (Figure 
2).  Fluorination at the 9 C position enhances the biological activity of the synthetic 
glucocorticoids compared with cortisol, and insertion of the 1,2 carbon-carbon double bond 
selectively augments glucocorticoid over mineralocorticoid activity, decreasing the rate of 135 
metabolic clearance and prolonging the biological half-life in plasma.  Mineralocorticoid 
activity is eliminated in synthetic glucocorticoids by methylation at the 16 C position, and 
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betamethasone and dexamethasone are stereoisomers, with the 16-methyl group located in 
the α or β configuration (Figure 2).  Thus, while betamethasone and dexamethasone have 
negligible mineralocorticoid activity, their glucocorticoid potency is approximately 25-fold 140 
that of cortisol [42].  Further, experiments in fetal sheep have shown that the half-time for 
clearance from plasma is extended by approximately 6-8 h compared to cortisol [27]. 
 
Figure 2  
 145 
Babies born pre-term have a high risk of developing broncho-pulmonary dysplasia (BPD), a 
chronic lung disease affecting both the airways and parenchyma, that is defined as the need 
for oxygen supplementation for babies >36 weeks of age [43]. Significant inflammation is 
seen in the lungs of neonates suffering from BPD, which may lead to scarring and cellular 
abnormalities and it is also very predictive of future neurological impairment and long-term 150 
respiratory dysfunction [43] . BPD is resistant to many interventions, however treatment 
with synthetic steroids, which have anti-inflammatory as well as maturational effects, is one 
possible treatment option. Use of synthetic glucocorticoids in the immediate post-natal 
period has well known clinical benefits, most notably facilitating weaning from mechanical 
ventilation, thereby reducing mortality and morbidity associated with BPD [43].  155 
 
In the UK, women at risk of preterm birth, who are between 24 and 34 weeks of gestation, 
have a target coverage for antenatal glucocorticoid therapy of 85% [44].  Post-natal steroid 
use still affects around 8% of pre-term neonates, with many in this group having also been 
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exposed to antenatal therapy.  A retrospective analysis in North America estimated 160 
antenatal steroid coverage of infants also receiving neonatal steroids at 61-75% [45], also 
meaning that many babies will have been exposed to both ante- and post-natal steroid 
therapy.  In parallel to increasing treatment coverage, the rate of preterm birth globally 
does not seem to have decreased in recent years, being maintained a level of 10%; 11.4% 
being reported in 2010 [44].  Clearly, with the maintained number of fetuses at risk of 165 
preterm birth and the expected coverage, it is reasonable to predict that vast numbers of 
infants will continue to receive ante- and/or post-natal glucocorticoid therapy.  
 
Adverse effects of glucocorticoids in the perinatal period 
Despite clear life-saving beneficial effects of ante- and post-natal glucocorticoid therapy in 170 
the preterm infant, accruing evidence derived from human clinical studies (e.g.[46][47]) and 
from experimental studies in animal models (e.g.[48][49]) raise serious concerns about 
potential adverse long-term consequences for growth, neurological and cardiovascular 
function in the offspring (Table 1, below). 
 175 
Table 1 
 
Post-natal glucocorticoid treatment can stunt growth when administered in preterm human 
infants [50] and in animal models of preterm birth [51]. In animal models, both single and 
repeat doses of antenatal glucocorticoids lead to a growth restriction that persists to term 180 
9 
 
[52]. Interestingly, this effect is not seen if the fetus is injected directly compared with 
maternal treatment [52].  Therefore, fetal growth restriction resulting from maternal 
injection with synthetic glucocorticoids may partially be related to an increase in utero-
placental vascular resistance.  Accordingly, Jellyman and colleagues reported that human 
clinically-relevant doses of dexamethasone administered to sheep in the last third of 185 
pregnancy led to a significant increase in utero-placental vascular resistance measured in 
vivo directly by means of a chronically-implanted Transonic flow probe around one of the 
main uterine arteries [53].  Antenatal glucocorticoids are also associated with decreased 
placental weight, and alterations in placental amino acid transport [49]; further factors that 
affect fetal growth.  There is evidence in humans for alterations to placental amino acid 190 
transport, specifically that related to the system A transporters [54]. Studies in non-human 
primates also show intrauterine growth restriction following one or multiple doses of 
antenatal glucocorticoid therapy [52].   
 
Several animal studies investigating physiological consequences of peri-natal glucocorticoid 195 
exposure have reported a reduction in brain weight following glucocorticoid exposure. 
Specifically, this appears to be associated with a decrease in the volume of the cortical and 
deep grey matter as well as of the hippocampal neuronal soma [55][56]. Cellular alterations 
include delayed myelination [57], alterations in gap junction proteins [58], and specific 
changes in gene expression [57].   These are worrying reports since the use of steroids in the 200 
immediate post-natal period in infants born preterm rose during the 1990’s, with 
predominantly dexamethasone being administered [59]. However, it was soon observed 
that those children who had received post-natal glucocorticoids demonstrated immediate 
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and long-term adverse side effects from this treatment, including neurological impairment. 
In response, in 2002, the American Academy of Pediatrics released a consensus statement 205 
advising against the use of steroids for treatment of BPD [60]. The result was a sharp 
decrease in use of this therapy, except in the most severe cases of BPD.  However, since 
then, the DART study has indicated no strong association with long-term adverse 
consequences when low-dose dexamethasone treatment was trialled [61]. Consequently, 
post-natal treatment with glucocorticoids in neonates born preterm continues as routine 210 
practice.   
 
Studies have now begun to report impaired IQ and altered behaviour in young adults born 
preterm who were exposed to synthetic glucocorticoids during the perinatal period [62].  
There are also reports of altered stress and anxiety responses in children [63][64]. This may 215 
be secondary to alterations in the HPA axis [65] Follow-up studies report adolescents 
between ages 14-17 who have been exposed to postnatal dexamethasone to have adverse 
motor function, impaired neuropsychological test scores, and females present in these 
cohort were more likely to need special education measures [66]. This human group also 
displays decreased brain volumes, specifically of the white matter, thalami, and basal 220 
ganglia, with a potential dose-dependent relationship [67], and altered HPA axis function.  
Evidence derived from human clinical studies also shows altered stress responses following 
antenatal glucocorticoid exposure; for example, an increased plasma cortisol response to 
stress tests in adolescents [68]. In addition, there is accumulating animal evidence for 
programming of the fetal hippocampus by antenatal glucocorticoid exposure, including 225 
alterations in the fetal hippocampal methylome and acetylome [69], hippocampal 
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glucocorticoid receptor DNA binding patterns, and expression levels of both the 
glucocorticoid and mineralocorticoid receptors [70]. These alterations occur in a highly sex-
specific manner, with a greater impact in male offspring, and have been observed to lead to 
functional changes in hippocampal function [69].  230 
 
With regard to cardiovascular function,  adult men and women, whose mothers had 
received antenatal steroids, had decreased aortic distensibility and increased aortic arch 
pulse wave velocity.  Aortic stiffness in these individuals was similar to that of individuals a 
decade older [46]. In rodent studies, antenatal glucocorticoid exposure in animals born at 235 
term results in hypertension at adulthood [71][72]. However, due to the significant 
differences in maturation of the cardiovascular system and the longer and greater 
glucocorticoid exposure in these studies when compared to human clinical practice, the 
clinical relevance of these results has been called into question. In the sheep model of 
antenatal glucocorticoid exposure, in which the temporal development of the 240 
cardiovascular system is much more similar to humans [73], there is also a resulting 
hypertension in adulthood in offspring born at term [74]. However, these studies have 
typically used a much earlier window of glucocorticoid exposure than we would expect to 
see clinically (ranging from the equivalent of 7-8 to 22 weeks of human pregnancy). Human 
clinical follow up studies have also demonstrated an elevated blood pressure (see [48][49]) 245 
and impaired systolic and diastolic function  in exposed individuals born pre-term when 
compared to term born adults.  In such studies, it is clearly difficult to disentangle the partial 
adverse effect on blood pressure and cardiac function of being born pre-term with those 
triggered by glucocorticoid therapy itself. Hence, the relationship between antenatal 
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glucocorticoid exposure alone and raised blood pressure in adulthood remains unclear. 250 
Further, multiple independent studies in animal models have reported endothelial 
dysfunction [75][76] and cardiac ventricular wall remodelling [77] resulting from perinatal 
glucocorticoid therapy.  Importantly, these investigations include studies in experimental 
animal models with human clinically-relevant dosing regimens or actual studies in humans 
[47].   255 
 
A way forward? 
It is clear that the evidence supporting the life-saving clinical benefits of ante- and post-
natal glucocorticoid treatment of the preterm infant is overwhelming. Nevertheless, it is 
also clear that despite these very apparent beneficial effects, there is accumulating evidence 260 
for long-term detrimental side effects of ante- and post-natal glucocorticoid treatment.  
Therefore, there is interest in understanding the physiological mechanisms via which 
glucocorticoids promote these adversities in order to fine-tune current clinical therapy to 
maintain benefits while diminishing detrimental effects, thereby achieving the best of both 
worlds.   This is no trivial task. Because of the pleiotropic nature of glucocorticoids in 265 
different tissues and at different gestational ages, it is difficult to isolate specific mechanistic 
pathways. This problem is compounded by the use of multiple experimental animal models 
with varying ranges of temporal developmental milestones as well as use of several doses, 
routes and timings of administration.  Further, in humans, it is difficult to dissect the long-
term detrimental effects of preterm birth compared to the effects from glucocorticoid 270 
exposure alone. 
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One likely mechanistic pathway leading to detrimental consequences of synthetic 
glucocorticoids may relate to their capacity to induce oxidative stress.  Reactive oxygen 
species (ROS), such as the superoxide anion (O-) perform essential cellular signalling 275 
processes in the brain and circulatory system [78]. These effects are predominantly 
mediated by interaction with a plethora of other cellular molecules, in a highly integrated 
system. ROS also contribute to vascular resistance, principally by reacting with nitric oxide 
(NO) and H2S, establishing a resultant oxidant tone in the circulation [79].  Excessive ROS 
production and/or a decrease in antioxidant defences induces oxidative stress and increases 280 
vascular resistance to blood flow [79].   This vascular oxidant tone is functional in fetal life 
and it can be manipulated so that an increase in the O-:NO ratio promotes vasoconstriction 
while a decrease leads to vasodilatation in several vascular beds, including the umbilical 
circulation [80][81].  Accumulating evidence suggests that one pathway by which 
glucocorticoids may promote their deleterious effects is through the inappropriate 285 
generation of ROS and consequent decreased NO bioavailability. For instance, 
glucocorticoids are known to activate pro-oxidant systems, such as xanthine oxidase, and 
the antioxidant tempol reverses dexamethasone-induced hypertension in the adult rat 
[82][83].  Once generated, ROS may subsequently damage cellular components, affect 
signalling pathways, and alter the oxidant tone of the vasculature by decreasing NO 290 
availability. There is also evidence of oxidative stress in the cardiovascular system and brain 
in humans and in animal models of antenatal glucocorticoid exposure [57][82] and HUVEC 
(Human Umbilical Vein Endothelial Cells) treated with dexamethasone show an increase in 
hydrogen peroxide production and decreases in cellular NO, secondary to ROS production 
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via NAD(P)H oxidase, xanthine oxidase, and the mitochondrial electron transport chain [82]. 295 
In humans, there is also evidence that glucocorticoids may cause an acute repression of the 
key antioxidant glutathione peroxidase 3 (GPx3) [84]. It is therefore possible that the 
adverse effects of glucocorticoids on the developing brain and cardiovascular system are 
secondary to the generation of oxidative stress, with a subsequent decrease in the 
bioavailability of NO.  In a series of studies, Giussani and colleagues have tested the 300 
hypothesis that combined antioxidant and glucocorticoid therapy is safer than 
glucocorticoid treatment alone for the treatment of preterm birth. 
 
Combined glucocorticoid and antioxidant therapy in the perinatal period 
The newborn rat is an established experimental model of human prematurity, as postnatal 305 
development of respiratory, cardiovascular and neuronal function in this species compares 
with pre-natal milestones in the human [85].  A first series of studies showed that postnatal 
treatment of newborn rat pups with a human clinically-relevant tapering course of 
dexamethasone induced multiple indices of increased cerebral oxidative stress and 
decreased total brain volume and the soma volume of neurons in the CA1 region and in the 310 
dentate gyrus of the hippocampus, when measured at weaning [86].  Further, neonatal 
dexamethasone treatment in the rat increased cardiac oxidative stress, induced left 
ventricle wall thinning with aortic wall remodeling, it increased constrictor reactivity to 
phenylephrine and thromboxane while it impaired endothelium-dependent vasorelaxation 
in the femoral circulation, when measured at weaning [76][87].  Investigation of the longer 315 
term effects of postnatal dexamethasone treatment in the adult rat revealed lower 
circulating plasma NOx, left ventricular wall hypertrophy with significant diastolic 
15 
 
dysfunction and these hearts failed to adapt output to increased preload or afterload, 
indicating a compromised cardiac Starling mechanism [88] (Figure 3).  Combined treatment 
of newborn rat pups with dexamethasone and the antioxidant vitamins C and E protected 320 
against the shorter- and longer-term detrimental effects of dexamethasone on the brain, 
the heart and the peripheral vasculature [76][86-88] (Figure 3). 
 
Further studies have tested whether agents that are not antioxidants per se but are known 
to increase NO bioavailability could also be used to diminish the adverse side-effects of 325 
postnatal glucocorticoid therapy.  In addition to their established cholesterol-lowering 
effects, statins have additional beneficial actions by increasing NO bioavailability [88].  
Indeed, clinical and experimental evidence suggests that the pleiotropic effects of statins, by 
improving endothelial function, might be useful for the treatment of neurological disorders, 
such as Parkinson’s and Alzheimer’s disease, ischaemic stroke and vascular 330 
dementia[89][90]. Recent experiments have confirmed that postnatal treatment of rat pups 
with dexamethasone in human clinically-relevant doses decreased regional brain and 
hippocampal soma volumes, reduced cortical neuronal number while increasing the density 
of white matter GFAP-positive astrocytes when measured at weaning [55]. Dexamethasone 
combined with pravastatin treatment restored circulating NOx and prevented the adverse 335 
effects of dexamethasone on the developing brain at weaning [55] (Figure 4).  In an elegant 
study by Wyrwoll and colleagues, it was also reported that pravastatin normalized placental 
vascular defects, fetal growth and cardiac function in a murine model of glucocorticoid 
excess [91].  
 340 
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Figure 3 
 
Figure 4 
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Collectively, these studies provide strong evidence to support that combined antioxidant 
and glucocorticoid therapy may be safer than glucocorticoid therapy alone for the 
treatment of preterm birth. Future work will determine if these beneficial effects of 
postnatal glucocorticoid and antioxidant therapy may also be advanced to the ante-natal 
period. Since ante-natal glucocorticoids are administered more or less at the point of 350 
diagnosis of pre-term birth, there is a limited window for intervention. This means that the 
design of combined glucocorticoid and antioxidant therapy to be administered 
simultaneously could be of significant clinical value.  More generally, these studies provide 
evidence of proof-of-principle supporting that it is possible to minimise the detrimental 
effects of glucocorticoid treatment while maintaining their clinical benefits in the perinatal 355 
period. The ultimate goal in the field is to be able translate these findings to the human 
clinical setting and to move towards a combined antioxidant and glucocorticoid therapy for 
the safer treatment of preterm birth. 
Box 1 Clinician’s Corner Box:  
 Synthetic glucocorticoids are routinely administered during the perinatal period in 
instances of pre-term birth. Despite clear life-saving beneficial effects, growing 
evidence suggests long-term detrimental consequences for the offspring growth, 
brain and cardiovascular development. 
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 If we can better understand the physiological mechanisms resulting in these adverse 
side effects of synthetic glucocorticoids, we could fine-tune current clinical 
treatment to minimise adverse side-effects whilst maintaining the clinical benefits. 
 Combined antioxidant and glucocorticoid therapy may be safer for the treatment of 
preterm birth and the hypothesis the Giussani laboratory proposes needs to be 
tested in human clinical trials.  
 
Outstanding Questions Box: 
 Which mechanisms in addition to increased oxidative stress contribute to the 
detrimental effects on the offspring of glucocorticoid exposure during the perinatal 
period? 
 Does combined antioxidant and glucocorticoid therapy maintain beneficial effects 
and minimise detrimental effects on the offspring when administered ante-natally? 
 In contrast to rodents, which are mostly altricial species, humans and sheep share 
similar temporal developmental milestones in terms of cerebral, cardiovascular and 
pulmonary maturation. Does combined antioxidant and glucocorticoid therapy 
maintain beneficial effects and minimise detrimental effects on the offspring when 
administered in ovine models of preterm birth? 
 Does combined antioxidant and glucocorticoid therapy maintain beneficial effects 
and minimise detrimental effects on the offspring when administered in human 
pregnancy threatened with preterm birth?  
 
Highlights Box: 
 Antenatal glucocorticoid therapy accelerates fetal lung maturation and treatment of 
the preterm infant with glucocorticoids reduces the incidence of chronic lung disease 
and the baby’s dependence on assisted ventilation.  Therefore, perinatal 
glucocorticoid therapy has led to a significant reduction in morbidity and mortality of 
the baby born preterm. 
 Despite established beneficial effects, there is increasing evidence that exposure of 
the offspring to synthetic glucocorticoids during the perinatal period induces long 
term detrimental effects on growth, the brain and the cardiovascular system. 
 Glucocorticoid therapy in the perinatal period is here to stay.  However, current 
therapy needs refining to maintain benefits but also limit detrimental effects.   
 Detrimental effects of glucocorticoid therapy are partly mediated by increased 
oxidative stress. 
 We propose combined antioxidant and glucocorticoid therapy may be the safer for 
the treatment of preterm birth.  
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Glossary: 
 Ante-natal – during pregnancy, the period prior to birth. 
 Post-natal – the period after birth, the immediate post-natal period refers to the 
first 6 weeks following birth. 
 Neonate – a new born child or mammal. 
 Peri-natal – relating to the period shortly before and after birth. 
 Bi-nucleation – maturational change in which heart cells switch from a single nucleus 
to two nuclei per cell, which is a terminal differentiation evet as cells no longer 
proliferate after undergoing this change. 
 Bradycardia – reduced heart rate in response to a physiological stressor. 
 FeNa – Fractional excretion of sodium ions (Na+) by the kidney, refers to the % of 
Na+ that passes through the kidney, that is eventually excreted in the urine. 
 Utero-placental – referring to the uterus and placenta as a functional unit. 
 Peripheral vascular resistance – resistance to blood flow in the body’s peripheral 
circulations, which consist of responsive vessels that may rapidly alter their state 
from constriction to dilatation to modulate local blood flow.  Key examples of 
peripheral circulations that contribute to peripheral vascular resistance are the 
mesenteric and femoral vascular beds. 
 Aortic distensibility and pulse wave velocity - Aortic distensibility and aortic pulse 
wave velocity (PWV) are two parameters closely related to the elastic function of the 
aorta and the ability of this vessel to distend.   The parameters serve as pathogenic 
markers in cardiovascular disease. 
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Figure 1. Roles of glucocorticoids in fetal maturation. Key maturational events associated with the prepartum cortisol rise in: the cardiovascular 
system, the HPA axis, fetal metabolism, the nervous system, the fetal lungs, and the kidneys.  
HPA Axis 
• Increased POMC production in the 
hypothalamus [30] 
• Increased ACTH sensitivity of adrenal 
cortex [29][31] 
• Increased plasma cortisol response to 
acute stress [31] 
Metabolism: 
• Increased gluconeogenic 
capacity [11][49] 
• Production of digestive enzymes 
[11][49] 
• Switch towards metabolism of 
fatty acids [11][49] 
 
Nervous System: 
• Division of glia and astrocytes [17] 
• Neuronal migration [16][17] 
• Synapse formation [16][17] 
• Programmed cell death [17][18] 
Lungs: 
• Increased elasticity [12][14] 
• Lung liquid removal [12][13] 
• Surfactant production [6][15] 
• Antioxidant capacity [6][15] 
Kidneys: 
• Decreased fractional excretion 
of Na+ [32][33] 
• Increased GFR [33][35] 
• Increased renin production 
[19][38][39] 
• Decreased nephrogenesis [37] 
Cardiovascular System: 
• Increased blood pressure [19][20] 
• Increased cardiac contractility [2][23][24] 
• Increased cardiac output [24] 
• Altered baroreflex and cardiovascular responses 
to acute stress [21][22][25][27][28] 
Figure 2. Chemical structures of the synthetic glucocorticoids: Betamethasone and Dexamethasone. A) Betamethasone, where * 
highlights the C1-C2 double bond, † highlights the fluorination of C9, and  ‡ highlights the stereoisomeric methyl group. B) 
Dexamethasone, where * highlights the C1-C2 double bond, † highlights the fluorination of C9, and  ‡ highlights the stereoisomeric 
methyl group.  
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Figure 3. Effect of postnatal dexamethasone on the brain.  A. 
Coronal sections of control and dexamethasone-treated rat pups on 
postnatal day 22.  Dexamethasone was injected i.m. to rat pups 
during the first three days of life using a human clinically-relevant 
dose. Scale bar is 2.5 mm. B. Total brain volume and volumes of 
deep grey matter, hippocampus, white matter, and cortex, at 
postnatal day 21 in control (n = 8), dexamethasone (n = 7), 
dexamethasone with pravastatin (n = 8), and control with 
pravastatin (n = 7) pups. Blue bar: deep grey matter; black bar: 
hippocampus; red bar: white matter; white bar: cortex. *P < 0.05 
vs. control; †P < 0.05 vs. control with pravastatin; ‡P < 0.05 vs. 
dexamethasone with pravastatin (ANOVA + Student-Newman-
Keuls). Redrawn from Tijsseling et al. Ped Res. 74, 639-45 (2013) 
with permission. 
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Figure 4.   Effect of postnatal dexamethasone on the heart.  Values are 
mean ± S.E.M. for A) systolic function (left ventricular developed 
pressure, LVDP), B) diastolic function (left ventricular end diastolic 
pressure, LVEDP), C) cardiac output (CO) in response to pre-load and D) 
cardiac output in response to after-load in control pups (n=7), pups 
treated with dexamethasone (D, n=6), pups treated with 
dexamethasone combined with vitamins C and E (DCE, n=7) and 
control pups treated with vitamins C and E (CCE, n=7).  Significant 
differences (P<0.05) are: *, vs C; †, vs D, (ANOVA + Tukey test). 
Redrawn from Niu et al. J Physiol. 591(Pt 20), 5083-93 (2013) with 
permission. 
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Table 1. Evidence for detrimental effects of peri-natal glucocorticoid exposure. Key findings in different systems demonstrating detrimental effects 
following glucocorticoid administration in the human clinical data as well as in experimental animal models: rodents, sheep, non-human primates.  
Supporting references are linked to the various physiological systems by use of different coloured text.  
Species Nervous System Cardiovascular System Renal System Key References 
Rodent Reduced brain weight, 
reduced volume of 
cortex, hippocampus and 
deep grey matter, 
impaired motor 
development 
Hypertension, cardiac 
diastolic dysfunction, 
impaired Starling 
mechanism, endothelial 
dysfunction 
Impaired renin 
production, increased 
urine angiotensin 
II/creatinine levels and 
reduced renal 11b-HSD2 
activity  
[17][18][55][63][69][71] 
[72][76][77][86][83][87] 
[88][91] 
Sheep Altered HPA axis activity, 
decreased brain weight, 
increased sympathetic 
activity, delayed 
myelination, altered gap 
junctions 
Hypertension, 
endothelial dysfunction, 
left ventricular 
hypertrophy 
Decreased nephron 
number, increased 
glomerular volume, 
altered renin production, 
altered RAS sensitivity 
[19][21][22][24][25][27] 
[28][31][34][38][39][53] 
[57][58][74][75] 
Human and Non-human 
Primates 
Unfavourable behaviour 
scores, altered HPA 
activity, more likely to be 
in lowest achievement 
group at school, 
increased stress 
responses 
Increased aortic stiffness, 
increased blood pressure 
and altered glucose 
metabolism 
Lower GFR at 19 years [36][46][47][56][62][64][
65][66][67] 
